SIC 2836 - Biological Products, Except Diagnostic Substances
Establishments primarily engaged in the production of bacterial and virus vaccines, toxoids, and analogous products (such as allergenic extracts), serums, plasmas, and other blood derivatives for human or veterinary use, other than in vitro and in vivo diagnostic substances. Included in this industry are establishments primarily engaged in the production of microbiological products for other uses. Establishments primarily engaged in manufacturing in vitro and in vivo diagnostic substances are classified in Industry 2835.
Industry trends:
The Biological Products industry (NAICS 2836), which excludes diagnostic substances, is experiencing several significant trends. Firstly, there is a strong emphasis on advanced biotechnology applications, including the use of CRISPR and other gene-editing technologies. These innovations are driving the development of personalized medicine and targeted therapies, reflecting a shift towards more precise and effective treatments.
Another notable trend is the growing interest in biopharmaceutical outsourcing, as companies seek to leverage specialized expertise and reduce time-to-market. Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) are playing increasingly crucial roles in the development and production processes.
Additionally, the industry is seeing substantial investment in bioprocessing technologies, which aim to enhance efficiency and scalability. Continuous bioprocessing and single-use technologies are gaining traction, offering flexible and cost-effective solutions for biologics production.
The regulatory environment is also evolving, with agencies like the FDA and EMA providing clearer guidelines on biosimilars and novel biologics. This regulatory clarity is expected to accelerate market entry and foster innovation.
Looking ahead, the forecast for the industry is positive, with sustained growth anticipated over the next few years. The market for biologics is projected to expand due to rising demand for innovative therapies and the increased prevalence of chronic diseases. Furthermore, advancements in biotechnology will likely continue to drive transformative changes, positioning the industry for a robust future.
This industry is comprised of:
Agar culture media, except in vitro and in vivo
Aggressins, except in vitro and in vivo
Allergenic extracts, except in vitro and in vivo
Allergens
Anti-hog-cholera serums
Antigens
Antiserums
Antitoxins
Antivenin
Bacterial vaccines
Bacterins, except in vitro and in vivo
Bacteriological media, except in vitro and in vivo
Biological and allied products: antitoxins, bacterins, vaccines, viruses,
Blood derivatives, for human or veterinary use, except in vitro and
Coagulation products
Culture media or concentrates, except in vitro and in vivo
Diphtheria toxin
Hematology products, except in vitro and in vivo reagents
Plasmas
Pollen extracts, except in vitro and in vivo
Serobacterins
Serums, except in vitro and in vivo
Toxins
Toxoids except in vitro and in vivo
Tuberculins
Vaccines
Venoms
Viruses
This report includes the ability to segment your Industry by:
- Region
- Employees
- Net Sales
- Company Age
- Total Assets
- Ownership Type
With iCFO You Get
What Is iCFO?
A review and comparison of financial performance of privately-help companies in specified SIC/NAICS industry segment, using industry standard benchmarks.
Sound Business Analysis
Answers come easily with iCFO. Review ROI, sales per employee, profit margins of the top 10%, top 25% and more, to identify areas of concern and opportunity. Examine what if scenarios and P&L impact of reducing costs or adding revenue.
Your Business’ Health In Minutes
It takes only five minutes to enter your data and produce a concise profile of your company’s fiscal state, including critical business ratios focusing on liquidity, profitability, asset efficiency, and growth.